Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT06555848

CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage Procedure

CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage Procedure — Recruiting • Infectious Disease • NCT06555848.

📅 04 May 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06555848
Sponsor
BONESUPPORT AB
Start
2025-06-02
ClinicaliQ Trial Snapshot
  • CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage Procedure — Recruiting • Infectious Disease • NCT06555848.
  • What is being tested: CERAMENT G (an antibiotic-loaded bone void filler) is being evaluated as part of single-stage surgical treatment for osteomyelitis, combining debridement and reconstruction in one procedure rather than traditional two-stage approaches.
  • Patient eligibility overview: The study includes subjects undergoing single-stage surgical treatment for osteomyelitis where CERAMENT G was used as an adjunct to standard surgical debridement and management.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The study is a prospective cohort study of subjects where CERAMENT G was used as part of the surgical treatment of osteomyelitis in a single stage procedure.

Eligibility Snapshot
  • : Subjects meeting the following inclusion criteria are to be included in the analysis: 1. Patients receiving CERAMENT G subsequent to surgical excision of osteomyelitis, with Cierny-Mader classification grades III or IV, who require dead-space management of a bone defect following surgical debridement and excision of infection. 2. Symptoms for a minimum of six months with clinical and radiological features accompanied by at least one of the following: 1. the presence of a sinus 2. the presence of an abscess or intra-operative pus 3. the presence of positive supportive histology 4. two or more microbiological cultures with indistinguishable organisms (defined as cultures resulting in identification of the same microbe (e.g., Staph aureus) with similar antimicrobial sensitivity) Notes: In cases where cultures are negative, a patient will be included in the study only if there is positive supportive histology combined with the presence of a draining sinus or intra-operative pus. Infected non-unions will be included only if the bone loss is < 1cm after debridement and excision of bone has been performed.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Survey reveals 1 in 3 parents believe children always need antibiotics for ear infections
Infectious Disease · UKHSA · 11 Mar 2026
One-third of parents incorrectly believe antibiotics are always necessary for childhood ear infections, indicating a significant gap in public understanding of appropriate…
View brief →
Clinical Brief
Stay at home advice questioned and rules too tough – key findings from Covid report
Infectious Disease · BBC Health · 19 Mar 2026
An NHS close to collapse, patients failed and NHS staff put at risk - what you need to know. This update is…
View brief →
Clinical Brief
Pregnancy vaccine reduces baby hospital admissions for RSV by 80%
Infectious Disease · BBC Health · 17 Apr 2026
Maternal RSV vaccination reduces infant hospitalisation risk by 80%, offering significant protection against severe lower respiratory tract infection in the first months…
View brief →
Guideline
Sepsis: Recognition, Diagnosis and Early Management (NICE NG51)
Infectious Disease · 27 Mar 2026
Use qSOFA tool (altered mental state, systolic BP ≤100 mmHg, respiratory rate ≥22) or NEWS2 score to identify suspected sepsis in adults…
View guideline →
Guideline
Antimicrobial Stewardship: Systems and Processes for Effective Antimicrobial Medicine Use (NICE NG15)
Infectious Disease · 25 Mar 2026
Document the clinical indication, dose, route, and planned review/stop date on every antibiotic prescription at the point of initiation Review all intravenous…
View guideline →
Clinical Brief
Midwives remain the most trusted source of information on pregnancy vaccination
Infectious Disease · UKHSA · 11 Mar 2026
Over 60% of pregnant women cite healthcare professional recommendation as a key driver for vaccine uptake, highlighting the critical influence of clinical…
View brief →